Award voor CPCT, CZ en Vitromics

Award for project “public-private partnership addresses overtreatment issue in oncology”

On April 10th CZ, Vitromics and CPCT were awarded the Value Based Healthcare Prize for most exceptional initiative in cost-efficiency.The quality of your project is truly inspiring to us and probably to other healthcare participants as well.

Value Based Healthcare Center Europe awarded 4 prizes: the first prize and 3 prizes for the most exceptional initiatives in cost-efficiency, collaborations and patient outcomes. VBHCE received 30 projects with a truly high quality and potential. This has made the selection of nominees extremely interesting and challenging.


You can read more on including the blog:

Focus on personalised medicine in addressing over- treatment

Over-treatment of patients is unfortunately not an uncommon phenomenon in healthcare. Therapies rarely work well for everybody in a treated group. Patients with no benefit from the treatment, do suffer from the negative side effects and incur delays in their optimal treatment path. Moreover, the healthcare budget is not used effectively . However, physicians often have no alternative to prescribing these therapies to the whole patient group in the absence of diagnostic tools for preselecting patients as potential responders or non-responders.

This is exactly the situation where more personalised therapy (personalized medicine) can be beneficial for patients.

In the project “Public-private partnership addresses overtreatment issue in oncology” Dutch healthcare insurer CZ, the Center for Personalized Cancer Treatment (CPCT) and VitrOmics, a company specialised in personalized medicine, team up. The collaborators are aiming to develop a new protocol which will preselect those women that will have a higher chance of benefitting from the treatment with

exemestane and everolimus versus the women that will have no or very limited benefit from the therapy. Future patients’, doctors’, health insurance companies’ and technology innovators’ interests are uniquely aligned in this study. Even though patients treatment will not change in this observational trial, patients benefit from the study as their tumours are analysed in great molecular detail. Providing a molecular tumour “passport” can be, in the light of all the discoveries in this field, crucial information available to the doctor when the disease progresses.

This project clearly shows how over-treatment can be addressed by changing treatment benefit, raising the quality of care provided and helping to spend the healthcare budget more efficiently.